Publication:
Controlled release of interleukin-2 from chitosan microspheres

dc.contributor.authorÖZBAŞ, SUNA
dc.contributor.authorsOzbas-Turan, S; Akbuga, J; Aral, C
dc.date.accessioned2022-03-12T16:59:00Z
dc.date.accessioned2026-01-11T19:10:30Z
dc.date.available2022-03-12T16:59:00Z
dc.date.issued2002
dc.description.abstractChitosan microspheres were evaluated for sustained-release of recombinant human interleukin-2 (rIL-2) in this study. In addition, the effects of different formulation factors, such as chitosan and protein concentrations, the volume of sodium sulfate solution, addition technique of rIL-2, and presence of glutaraldehyde during the encapsulation process, on microsphere characteristics were investigated. Chitosan microspheres containing rIL-2 were prepared by using the precipitation technique. The average diameter of microspheres was between 1.11-1.59 mum. Recombinant IL-2 encapsulation efficiency in these micropheres was high (75-98%). Formulation factors had no effect on the microsphere size. Recombinant IL-2 had been released from chitosan microspheres over a period of 3 months. The encapsulated rIL-2 remained biologically active and could be completely recovered from the release medium. Briefly, rIL-2 was released from chitosan microspheres in a sustained manner. The efficacy of rIL-2 loaded chitosan microspheres was studied using two model cells, HeLa and L-strain cell lines. Chitosan microspheres were added to the cells at different concentrations, and the amount of rIL-2 was assayed using the ELISA kit. Cell culture studies indicated that microspheres were uptaken by cells, and rIL-2 was released from the microspheres. Cellular uptake of rIL-2-loaded microspheres was dose dependent. It can be said that chitosan microsphere is a suitable carrier for rIL-2 delivery. (C) 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association.
dc.identifier.doi10.1002/jps.10122
dc.identifier.issn0022-3549
dc.identifier.pubmed11977100
dc.identifier.urihttps://hdl.handle.net/11424/227136
dc.identifier.wosWOS:000175407400005
dc.language.isoeng
dc.publisherJOHN WILEY & SONS INC
dc.relation.ispartofJOURNAL OF PHARMACEUTICAL SCIENCES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectinterleukin-2
dc.subjectchitosan microspheres
dc.subjectprecipitation technique
dc.subjectPREDNISOLONE SODIUM-PHOSPHATE
dc.subjectBIODEGRADABLE MICROSPHERES
dc.subjectRECOMBINANT INTERLEUKIN-2
dc.subjectIMMUNOTHERAPY
dc.subjectENHANCEMENT
dc.subjectLIPOSOMES
dc.subjectDELIVERY
dc.subjectINVIVO
dc.subjectCANCER
dc.subjectMODEL
dc.titleControlled release of interleukin-2 from chitosan microspheres
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage1251
oaire.citation.issue5
oaire.citation.startPage1245
oaire.citation.titleJOURNAL OF PHARMACEUTICAL SCIENCES
oaire.citation.volume91

Files